Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice
Restricted accessReview articleFirst published online August, 2011
Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice
Objectives: The purposes of our study were to evaluate the effect of intraperitoneal albendazole on tumor growth, ascites formation, and vascular endothelial growth factor (VEGF) mRNA expression, and to assess the synergistic effect of paclitaxel in OVCAR-3-bearing nude mice. Methods: In all, 4 groups of mice were injected intraperitoneally with weekly albendazole (450 mg/kg per week), paclitaxel (30 mg/kg per week), albendazole plus paclitaxel, or normal saline for 4 weeks. Results: Ascitic fluid accumulation (2.47, 2.65, 2.88, and 5.90 mL, respectively) and in ascitic VEGF levels were significantly reduced in the 3 treatment groups compared to the control group (170.83, 229.16, 267, and 1625 pg/mL, respectively). However, complete tumor suppression was more prominent in the paclitaxel group, and VEGF mRNA expression was more strongly inhibited in the albendazole group (P < .05). No synergistic effect of albendazole and paclitaxel was observed. Conclusion: We demonstrated a differential effect of albendazole and paclitaxel in a xenograft model of ovarian carcinoma; albendazole suppressed ascites formation by inhibiting VEGF secretion, and paclitaxel exerted its effects by direct cytotoxicity.
JemalASiegelRWardEMurrayTXuJThunMJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.
2.
BoocockCACharnock-JonesDSSharkeyAM. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87(7):506–516.
3.
OzolsRFWillsonJKWeltzMDGrotzingerKRMyersCEYoungRC. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res. 1980;40(11):4109–4112.
4.
KraftAWeindelKOchsA. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178–187.
5.
KimKJLiBWinerJ. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–844.
6.
YukitaAAsanoMOkamotoTMizutaniSSuzukiH. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res. 2000;20(1A):155–160.
7.
HuLHofmannJZaloudekCFerraraNHamiltonTJaffeRB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002;161(5):1917–1924.
8.
ByrneATRossLHolashJ. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721–5728.
9.
LiuJYangGThompson-LanzaJA. A genetically defined model for human ovarian cancer. Cancer Res. 2004;64(5):1655–1663.
10.
MonkBJChoiDCPugmireGBurgerRA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2005;96(3):902–905.
11.
CohnDEValmadreSResnickKEEatonLACopelandLJFowlerJM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102(2):134–139.
12.
WrightJDHagemannARaderJS. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer. 2006;107(1):83–89.
13.
HortonJ. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. 2000;121 Suppl:S113–S132.
14.
BarrowmanMMMarrinerSEBoganJA. The binding and subsequent inhibition of tubulin polymerization in Ascaris suum (in vitro) by benzimidazole anthelmintics. Biochem Pharmacol. 1984;33(19):3037–3040.
15.
LaceyE. Mode of action of benzimidazoles. Parasitol Today. 1990;6(4):112–115.
16.
PourgholamiMHWoonLAlmajdRAkhterJBoweryPMorrisDL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett. 2001;165(1):43–49.
17.
PourgholamiMHAkhterJWangLLuYMorrisDL. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2005;55(5):425–432.
18.
PourgholamiMHYan CaiZLuYWangLMorrisDL. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res. 2006;12(6):1928–1935.
19.
MukhopadhyayTSasakiJRameshRRothJA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002;8(9):2963–2969.
20.
SasakiJRameshRChadaSGomyoYRothJAMukhopadhyayT. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002;1(13):1201–1209.
21.
FerraraNHillanKJGerberHPNovotnyW. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.
22.
SinghalPLeleS. Intraperitoneal chemotherapy for ovarian cancer: where are we now?J Natl Compr Cancer Netw. 2006;4(9):941–946.
23.
TeicherBAHoldenSAAraG. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer. 1995;61(5):732–737.
24.
SatohHIshikawaHFujimotoM. Combined effects of TNP-470 and taxol in human non-small cell lung cancer cell lines. Anticancer Res. 1998;18(2A):1027–1030.
25.
PlacidiLScottECEckoffDBynonSSommadossiJP. Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes. Drug Metab Dispos. 1999;27(5):623–626.
26.
ShishidoTYasoshimaTDennoRMukaiyaMSatoNHirataK. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res. 1998;89(9):963–969.
27.
KlementGBaruchelSRakJ. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105(8):R15–R24.
28.
HuLHofmannJHolashJYancopoulosGDSoodAKJaffeRB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005;11(19 pt 1):6966–6971.
29.
ThakerPHYaziciSNilssonMB. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res. 2005;11(13):4923–4933.
30.
KamatAAKimTJLandenCNJr. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007;67(1):281–288.
31.
HanahanDBergersGBergslandE. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045–1047.
32.
BrowderTButterfieldCEKralingBM. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878–1886.
33.
KerbelRSKamenBA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423–436.
34.
MengFHensonRPatelT. Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells. Am J Physiol Cell Physiol. 2007;293(2):C749–C760.
35.
KimHSOhJMJinDHYangKHMoonEY. Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production. Pharmacology. 2008;81(4):317–324.
36.
CellettiFLWaughJMAmabilePGKaoEYBoroumandSDakeMD. Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol. 2002;13(7):703–707.
37.
KlosKSZhouXLeeS. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 2003;98(7):1377–1385.
38.
LauDHXueLYoungLJBurkePACheungAT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999;14(1):31–36.
39.
XuGPanJMartinCYeungSC. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(4):1769–1777.
